What Do STEP-3's Results Actually Cost, and Are They Worth It?

At a glance

| Detail | Value | |---|---| | Trial | STEP-3 | | N | 611 | | Intervention | Semaglutide 2.4 mg subcutaneous weekly + intensive behavioral therapy (IBT) | | Comparator | Placebo + IBT | | Duration | 68 weeks | | Primary endpoint | Percentage change in body weight from baseline | | Key result | −16.0% (sema+IBT) vs −5.7% (placebo+IBT); estimated treatment difference −10.3 percentage points |

The Clinical Foundation for Economic Modeling

Before any cost model can be built, the underlying efficacy data must be strong. STEP-3 enrolled 611 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and randomized them 2:1 to semaglutide 2.4 mg or placebo, both layered on top of a 30-visit IBT program that included an initial 8-week low-calorie diet. The co-primary endpoints were percentage weight change and the proportion achieving ≥5% weight loss at 68 weeks.

What makes STEP-3 particularly relevant to economic modeling is that the comparator arm was not "usual care." Both groups received the same resource-intensive IBT program. The 5.7% weight loss in the placebo-plus-IBT arm reflects a meaningful active comparator, which means the incremental 10.3 percentage points attributable to semaglutide must justify its incremental cost above an already expensive behavioral intervention.

List Price vs Net Price: The Gap That Defines the Debate

Semaglutide 2.4 mg (branded as Wegovy) launched at a wholesale acquisition cost (WAC) of roughly $1,350 per month, translating to approximately $16,200 per year before rebates. Novo Nordisk has not disclosed net prices, but industry analysts and pharmacy benefit managers have estimated post-rebate costs in the range of $8,000 to $11,000 annually for commercially insured patients. For Medicare Part D enrollees, the Inflation Reduction Act's negotiation provisions may eventually compress this further, though anti-obesity medications have historically been excluded from Part D coverage under the Social Security Act's statutory exclusion.

The IBT component itself carries costs that are often ignored in drug-only models. A structured 30-session program comparable to what STEP-3 used typically runs $2,000 to $4,000 when delivered through dietitian-led group sessions, or considerably more with individual counseling. Any real-world cost-effectiveness estimate must account for this dual expense.

Published Cost-Effectiveness Analyses

The ICER Assessment

The Institute for Clinical and Economic Review (ICER) published its evidence report on anti-obesity medications in 2022, covering semaglutide 2.4 mg across the STEP program. Using a lifetime horizon microsimulation model, ICER estimated the cost per QALY for semaglutide at WAC exceeded $150,000, well above the commonly cited $100,000-to-$150,000 willingness-to-pay threshold in the United States. At a modeled "health-benefit price benchmark" (the net price ICER deemed cost-effective), semaglutide would need to cost roughly $7,500 to $9,800 per year.

ICER's model drew heavily on the STEP-1 through STEP-4 efficacy data. For the STEP-3 subgroup specifically, the addition of IBT improved absolute weight loss but also raised the total cost of the intervention package. Because STEP-3 showed that IBT added roughly 2 to 3 percentage points of weight loss on top of semaglutide alone (compared to the 12.4% in STEP-1 without IBT), the marginal cost-effectiveness of adding IBT to semaglutide becomes a separate and clinically important question.

Academic Cost-Utility Models

Several independent analyses have attempted to model semaglutide's long-term value. A 2023 analysis published in Obesity used a patient-level simulation to project cardiovascular events, type 2 diabetes incidence, and osteoarthritis progression averted over a 10-year horizon. When weight regain after drug discontinuation was modeled (consistent with STEP-1 extension data showing two-thirds regain within one year of stopping), the ICER rose sharply above $200,000 per QALY. When the model assumed indefinite treatment with sustained weight loss, the ICER fell below $100,000.

This "treatment duration assumption" is the single largest lever in every cost-effectiveness model for GLP-1 receptor agonists in obesity. Short-course treatment (68 weeks, as in STEP-3) may look favorable on a per-treatment-course basis, but the weight regain trajectory erodes the QALY gains rapidly.

The SELECT Trial's Downstream Impact on Value

The SELECT cardiovascular outcomes trial changed the economic calculus substantially. By demonstrating a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in patients with established cardiovascular disease and obesity, SELECT provided hard cardiovascular endpoints that cost-effectiveness models previously had to impute from observational data. Post-SELECT analyses suggest that for the subpopulation with both obesity and established atherosclerotic cardiovascular disease, semaglutide's ICER drops to $40,000 to $80,000 per QALY, depending on the time horizon and discount rate.

However, STEP-3's population was not selected for cardiovascular disease. Applying SELECT's MACE reduction to a lower-risk STEP-3 cohort would overestimate the cardiovascular benefit and underestimate the true ICER for that population.

Payer Coverage: A Fragmented Picture

Commercial Insurance

As of early 2026, commercial coverage for Wegovy has expanded substantially but remains uneven. Large self-insured employers increasingly cover anti-obesity medications, driven partly by the American Medical Association's recognition of obesity as a disease and by employer interest in reducing downstream costs from diabetes, joint replacement, and cardiovascular events. Prior authorization requirements typically mandate a documented BMI threshold, evidence of failed lifestyle modification (often 3 to 6 months), and sometimes a step-through requirement with older agents such as phentermine-topiramate or naltrexone-bupropion.

Medicare and Medicaid

Medicare Part D has historically excluded anti-obesity medications. The Treat and Reduce Obesity Act, reintroduced in multiple congressional sessions, would remove this exclusion but has not been enacted as of this writing. State Medicaid programs vary widely. Some cover anti-obesity drugs with extensive prior authorization, others exclude the entire class. This creates a two-tier access system that disproportionately affects the populations with the highest obesity prevalence and comorbidity burden.

The IBT Coverage Wrinkle

Medicare does cover IBT under a specific benefit category (HCPCS code G0447), but only when delivered by a primary care provider in a primary care setting, not by dietitians or in commercial weight management programs. This creates a practical barrier for replicating the STEP-3 protocol outside of clinical trials, since the structured 30-session program used in the trial does not map cleanly onto Medicare's IBT benefit structure.

Calculating Individual Value: A Framework for Patients

For an individual patient deciding whether to start semaglutide with or without IBT, the economic question differs from the societal cost-effectiveness question. The relevant inputs are:

| Factor | Favorable economics | Unfavorable economics | |---|---|---| | Out-of-pocket cost | Covered by insurance with low copay (<$50/month) | Full list price ($1,350/month) | | Comorbidity burden | Type 2 diabetes, ASCVD, NASH, severe OSA | Isolated obesity, low cardiometabolic risk | | Weight loss target | ≥15% (where pharmacotherapy offers clear marginal benefit over IBT alone) | <10% (achievable with IBT alone per STEP-3 placebo arm) | | Planned duration | Indefinite (sustained benefit) | Fixed course with planned discontinuation (regain risk high per extension data) | | Alternative therapies | Failed prior pharmacotherapy | Treatment-naive, eligible for lower-cost options |

The Endocrine Society's 2024 guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30 who have not met weight loss goals through lifestyle intervention alone, reinforcing that clinical appropriateness should precede any economic analysis.

Limitations of Current Economic Evidence

Several structural limitations affect every published cost-effectiveness analysis of the STEP-3 data:

Weight regain assumptions dominate outcomes. No published model has empirical long-term (5+ year) data on semaglutide continuation. All models extrapolate from 68-week trial data, and the assumptions about post-discontinuation regain or sustained treatment swing the ICER by 2x to 3x.

IBT cost heterogeneity. The 30-session IBT program in STEP-3 is not standardized in real-world practice. Models that assign a fixed IBT cost may over- or underestimate the true comparator cost by 50% or more depending on the delivery setting.

Comorbidity offsets are imputed, not observed. Reductions in diabetes incidence, cardiovascular events, and joint replacement are modeled from epidemiological associations, not from prospective data within STEP-3 itself. The SELECT trial provides direct cardiovascular endpoint data, but only for a higher-risk population.

Equity considerations are absent. Standard cost-per-QALY models do not capture the distributional impact of coverage policies that exclude Medicaid beneficiaries or Medicare enrollees from accessing treatment.

The Bottom Line for Clinicians and Payers

At current list prices, semaglutide 2.4 mg sits at or above conventional willingness-to-pay thresholds for the general obesity population studied in STEP-3. At plausible net prices, it enters the range most health economists consider acceptable, particularly for patients with multiple cardiometabolic comorbidities. The addition of IBT as used in STEP-3 improves absolute outcomes but its marginal cost-effectiveness over semaglutide alone has not been formally evaluated in a published head-to-head economic model.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
3. Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. FDA Label
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
6. Amaro A, Sugimoto D, Wharton S, et al. Efficacy and safety of semaglutide for weight management: evidence review and ICER assessment. Obesity. 2022. PubMed